Novavax Inc. jumped after US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

Health agencies working under Robert F. Kennedy Jr. are making changes to the nation's decades-old system for approving and ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

In other vaccine news, Health Secretary Robert F. Kennedy Jr. has officially ordered placebo testing on new vaccines, a change that experts claim will be costly and — harkening back to polio vaccine ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

In a world of increasing fragmentation and polarisation, the 78th World Health Assembly, starting Monday, will present itself ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

The US Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over ...

After a six-week long delay, The Food and Drug Administration (FDA) has finally approved a more traditional protein-based covid vaccine produced by pharmaceutical giant Novavax.

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.